Original Research
Neuroradiology/Head and Neck Imaging
July 29, 2020

Association of Coronavirus Disease (COVID-19) With Large Vessel Occlusion Strokes: A Case-Control Study

Abstract

To listen to the podcast associated with this article, please select one of the following: iTunes, Google Play, or direct download.
BACKGROUND. An increase in frequency of acute ischemic strokes has been observed among patients presenting with acute neurologic symptoms during the coronavirus disease (COVID-19) pandemic.
OBJECTIVE. The purpose of this study was to investigate the association between COVID-19 and stroke subtypes in patients presenting with acute neurologic symptoms.
METHODS. This retrospective case-control study included patients for whom a code for stroke was activated from March 16 to April 30, 2020, at any of six New York City hospitals that are part of a single health system. Demographic data (age, sex, and race or ethnicity), COVID-19 status, stroke-related risk factors, and clinical and imaging findings pertaining to stroke were collected. Univariate and multivariate analyses were conducted to evaluate the association between COVID-19 and stroke subtypes.
RESULTS. The study sample consisted of 329 patients for whom a code for stroke was activated (175 [53.2%] men, 154 [46.8%] women; mean age, 66.9 ± 14.9 [SD] years). Among the 329 patients, 35.3% (116) had acute ischemic stroke confirmed with imaging; 21.6% (71) had large vessel occlusion (LVO) stroke; and 14.6% (48) had small vessel occlusion (SVO) stroke. Among LVO strokes, the most common location was middle cerebral artery segments M1 and M2 (62.0% [44/71]). Multifocal LVOs were present in 9.9% (7/71) of LVO strokes. COVID-19 was present in 38.3% (126/329) of the patients. The 61.7% (203/329) of patients without COVID-19 formed the negative control group. Among individual stroke-related risk factors, only Hispanic ethnicity was significantly associated with COVID-19 (38.1% of patients with COVID-19 vs 20.7% of patients without COVID-19; p = 0.001). LVO was present in 31.7% of patients with COVID-19 compared with 15.3% of patients without COVID-19 (p = 0.001). SVO was present in 15.9% of patients with COVID-19 and 13.8% of patients without COVID-19 (p = 0.632). In multivariate analysis controlled for race and ethnicity, presence of COVID-19 had a significant independent association with LVO stroke (odds ratio, 2.4) compared with absence of COVID-19 (p = 0.011).
CONCLUSION. COVID-19 is associated with LVO strokes but not with SVO strokes.
CLINICAL IMPACT. Patients with COVID-19 presenting with acute neurologic symptoms warrant a lower threshold for suspicion of large vessel stroke, and prompt workup for large vessel stroke is recommended.
Coronavirus disease (COVID-19) is a clinical manifestation of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1], which was first detected in Wuhan, China, in December 2019 and declared a pandemic on March 11, 2020 [2]. COVID-19 most commonly presents with pneumonialike symptoms, including fever, dyspnea, cough, and severe hypoxia. However, the spectrum of clinical manifestations is broader and includes gastrointestinal disease, headache, altered mental status, anosmia, and confusion [3, 4].
Neurologic manifestations of COVID-19 have been described. In one study from China [4], neurologic symptoms were found in as many as 36% of patients admitted to the hospital with COVID-19. Common manifestations include altered mental status, dysarthria, aphasia, and diffuse corticospinal tract signs [5], many of which may be seen in patients with acute ischemic infarction. Study results have suggested that endothelial injury in the vessel walls is caused by SARS-CoV-2 binding to angiotensin-converting enzyme 2 (ACE-2) receptors. The result is activation of a cytokine cascade that aggravates the vessels and ultimately leads to vascular thrombosis [68]. The exact pathophysiologic mechanism of SARS-CoV-2 infection has not yet been identified in human cerebral vessels. ACE-2 receptors were initially reported in the heart, kidney, and testis [9], though they were later found to also be expressed ubiquitously throughout blood vessels and in the glial tissue of the brain [10]. Vascular thrombosis and a hypercoagulable state have been widely reported in patients with COVID-19, resulting in deep vein thrombosis [11, 12], myocardial infarction [13, 14], and pulmonary embolisms [1517]. Further case reports [18, 19] have described patients with COVID-19 presenting with large vessel strokes.
We have observed an increase in frequency of acute ischemic strokes in patients presenting with acute neurologic symptoms during the COVID-19 pandemic. To our knowledge, no study has assessed the association of COVID-19 with either large vessel or small vessel strokes. In this study, we investigated the association between COVID-19 and stroke subtypes in patients presenting with acute neurologic symptoms.

Methods

Study Design and Participants

This retrospective case-control study was compliant with HIPAA. Institutional review board approval was obtained on an expedited basis with a waiver of written informed consent. The study included patients from a single hospital system consisting of six hospitals across the New York City boroughs of Manhattan, Queens, and Brooklyn. From March 16 to April 30, 2020, the hospital system treated a total of 9814 patients with known COVID-19 status, 5862 of whom had positive test results for COVID-19 (Fig. 1). This included 1334 patients in the ICU, 1018 of whom had COVID-19. A stroke code was activated for 356 patients who had suspected acute stroke. This code is activated by any health care provider in the emergency department or inpatient areas to rule out an acute stroke when a patient has acute neurologic symptoms [2022]. Activation of the code prompts an immediate evaluation by the stroke rapid response team and is followed by neuroimaging consisting of head CT and vascular imaging, such as CT angiography of the head and neck. Brain MRI is often performed on the same or the next day.
Fig. 1 —Flowchart shows study inclusions and exclusions. COVID-19 = coronavirus disease, CTA = CT angiography, LVO = large vessel occlusion, SVO = small vessel occlusion.
Enrollment of patients was continuous throughout the study period. Patients were excluded if they died before neuroimaging (n = 7) or if they had no clinical data in the electronic medical record (EMR) (n = 20). This yielded a final sample of 329 patients. The distribution of patients across the three New York City boroughs was 266 patients from Manhattan, 41 patients from Queens, and 22 patients from Brooklyn.
HIGHLIGHTS
Key Finding
Coronavirus disease (COVID-19) is associated with large vessel occlusion stroke but not small vessel occlusion stroke. After stratification for race and ethnicity, the risk of large vessel stroke among patients with COVID-19 was 2.4 times as high as that among patients without COVID-19.
Importance
Physicians should lower their threshold of suspicion for large vessel stroke in patients with COVID-19 who present with acute neurologic symptoms.

Data Collection

Major vascular risk factors related to stroke, such as hypertension, coronary artery disease, diabetes mellitus type 2, atrial fibrillation, congestive heart failure, dyslipidemia, smoking status, National Institutes of Health (NIH) Stroke Scale score, laboratory data, and body mass index, were collected from the EMR. Demographic information (age, sex, and race or ethnicity), COVID-19 status, and time to presentation were also collected from the EMR. COVID-19 was confirmed by in-house in vitro reverse transcription–polymerase chain reaction (RT-PCR) testing of nasopharyngeal swabs (cobas 6800/8800 systems, Roche) under emergency authorization from the U.S. Food and Drug Administration. Patients were considered to not have COVID-19 if the RT-PCR result was negative. However, because of the suboptimal sensitivity of the RT-PCR [2325], if patients continued to experience typical pulmonary symptoms of COVID-19, such as cough and shortness of breath, and if chest CT or CT angiography showed typical features of COVID-19 (n = 6), these patients were considered to have COVID-19.

Imaging Analysis

All neuroimaging of each patient was retrospectively reviewed for presence of stroke, stroke subtype (LVO or SVO), and location. Assessed imaging included head CT (n = 329), CT angiography (n = 327), MRI (n = 250), MR angiography (n = 78), and digital subtraction angiography (n = 59). This retrospective review was performed by a fellowship-trained neuroradiologist (J. S., with 1 year of experience) blinded to radiology reports and clinical history, including COVID-19 status. A second reader (S. K., third-year radiology resident) blinded to other clinical history independently recorded this information on the basis of a retrospective review of the prospective clinical radiology reports (which had been interpreted by five neuroradiologists) for each patient's imaging. This second reader did not review the images when assessing the radiology reports. For patients with incongruency between the retrospective imaging review and the assessment of the prospective reports, the imaging was retrospectively reviewed by a third reader (P. B., fellowship-trained neuroradiologist with 4 years of experience) blinded to imaging reports and clinical data, whose assessment served as the final diagnosis.
Second-order vessel occlusions were counted as LVOs, as described by Rennert et al. [26]. Thus, LVOs included the internal carotid artery, middle cerebral artery segments M1 and M2, anterior cerebral artery segments A1 and A2, posterior cerebral artery segments P1 and P2, basilar artery, anterior inferior cerebellar artery, vertebral artery, and posterior inferior cerebellar artery. SVO was defined as perforating vessel occlusion not appreciable to the reader on vascular imaging that resulted in acute lacunar infarction on MRI and CT combined with CT angiography, MR angiography, and digital subtraction angiography findings.

Statistical Analysis

A univariate analysis was performed to evaluate for associations between stroke-related risk factors and COVID-19 status. The Pearson chi-square test was performed for categoric variables, and a t test was performed for continuous variables. To reduce confounding effects, stroke-related risk factors associated with COVID-19 status identified at univariate analysis were applied to a multivariate logistic regression analysis assessing the effect of COVID-19 status on stroke subtype outcome. Patients without COVID-19 formed a negative control group in these analyses. Analyses were conducted with the SPSS statistical package for Microsoft Windows (version 25, IBM).

Results

Clinical Characteristics of Study Sample

The study sample consisted of 329 patients for whom a code for stroke was activated (175 [53.2%] men, 154 [46.8%] women; mean age, 66.9 ± 14.9 [SD] years). The mean time from symptom onset to hospital presentation was 11.2 ± 7.6 hours. The mean NIH Stroke Scale score was 9.5 ± 8.5. COVID-19 was present in 38.3% (126/329) of all of the patients for whom a code for stroke was activated. The other 61.7% (203/329) of patients formed the negative control group.

Imaging Findings

The first two readers provided congruent imaging assessments in 97.6% (321/329) of cases. The third reader interpreted the imaging in the other 2.4% (8/329) to reach a final assessment. Acute ischemic stroke was found on imaging in 35.3% (116/329) of the sample. LVOs were found in 21.6% (71/329) and SVOs in 14.6% (48/329) of the patients (Table 1). The most commonly observed LVO [62.0% (44/71)] was middle cerebral artery segment M1-M2 occlusion. The second most frequent occlusion in patients with LVO stroke [21.1% (15/71)] was in the internal carotid artery. Multifocal LVOs were observed in only 9.9% (7/71) of patients with LVO stroke.
TABLE 1: Demographic Characteristics of Study Sample (n = 329)
CharacteristicResult
Age (y)66.9 ± 14.9
Sex 
 Female46.8 (154)
 Male53.2 (175)
Race or ethnicity 
 White30.1 (99)
 Black29.2 (96)
 Hispanic27.4 (90)
 Other7.9 (26)
 Unknown5.5 (18)
Acute ischemic infarct35.3 (116)
 Large vessel occlusionsa21.6 (71)
  Middle cerebral artery segments M1 and M213.4 (44)
  Anterior cerebral artery segments A1 and A20.6 (2)
  Posterior cerebral artery segments P1 and P21.5 (5)
  Vertebral artery2.1 (7)
  Basilar artery1.2 (4)
  Internal carotid artery4.6 (15)
  Multifocal2.1 (7)
 Small vessel occlusions14.6 (48)
COVID-19b38.3 (126)
Hypertension74.8 (246)
Diabetes mellitus type 246.8 (154)
Dyslipidemia43.8 (144)
History of smoking33.1 (109)
Coronary artery disease25.8 (85)
Atrial fibrillation15.8 (52)
Congestive heart failure9.4 (31)
Body mass index27.6 ± 6.5
NIH Stroke Scale score9.5 ± 8.5
Time to presentation (h)11.2 ± 7.6
D-Dimer level (pg/mL)7.9 ± 7.2
Erythrocyte sedimentation rate (mm/h)51.5 ± 14.7
C-reactive protein level (mg/L)86.5 ± 47.2

Note—Values are mean ± SD or percentage of patients with number of patients in parentheses.

a
Some patients had multiple occlusions.
b
Coronavirus disease (COVID-19) was confirmed by reverse transcription–polymerase chain reaction (RT-PCR) testing of nasal swab in all but six patients, who had negative RT-PCR results but pulmonary symptoms and chest imaging findings typical of COVID-19.

Univariate Associations of Coronavirus Disease With Clinical Characteristics and Imaging Findings

At univariate analysis, the only individual stroke-related risk factor significantly associated with COVID-19 was race or ethnicity (Table 2). Hispanic patients accounted for 38.1% of those with compared with 20.7% of patients without COVID-19 (p = 0.001). LVO was present in 31.7% of patients with COVID-19 compared with 15.3% of patients without COVID-19 (p = 0.001). SVO was present in 15.9% of patients with COVID-19 and 13.8% of patients without COVID-19 (p = 0.632).
TABLE 2: Univariate Comparisons of Stroke-Related Variables Between Patients With and Those Without Coronavirus Disease (COVID-19)
CharacteristicWith COVID-19 (n = 126)Without COVID-19 (n = 203)p
Age (y)65.6 ± 13.267.6 ± 15.90.532
Male sex61.1 (77)58.3 (98)0.109
Race or ethnicity   
 White20.6 (26)35.9 (73)0.003a
 Black31.7 (40)27.6 (56)0.419
 Hispanic38.1 (48)20.7 (42)< 0.001a
 Other7.1 (9)8.4 (17)0.687
 Unknown2.4 (3)7.4 (15)0.091
Large vessel occlusion31.7 (40)15.3 (31)0.001a
Small vessel occlusion15.9 (20)13.8 (28)0.632
Diabetes mellitus type 250.8 (64)44.3 (90)0.324
Hypertension76.2 (96)73.9 (150)0.699
Coronary artery disease20.6 (26)29.1 (59)0.104
Congestive heart failure21.9 (15)13.8 (28)0.072
Dyslipidemia42.1 (53)44.8 (91)0.728
Atrial fibrillation15.1 (19)17.2 (35)0.412
Smoking status32.5 (41)36 (73)0.278
BMI28.2 ± 7.427.2 ± 6.30.342
Time to presentation (h)11.5 ± 6.111.1 ± 6.50.131
NIH Stroke Scale score12.5 ± 6.87.9 ± 6.20.093
D-Dimer level (^g/mL)6.2 ± 5.14.0 ± 5.30.422
Erythrocyte sedimentation rate (mm/h)62.5 ± 24.137.8 ± 14.80.221
C-reactive protein level (mg/L)110.5 ± 51.148.7 ± 36.30.111

Note—Values are mean ± SD or percentage of patients with number of patients in parentheses. NIH = National Institutes of Health.

a
Statistically significant at p < 0.05.

Independent Association of Coronavirus Disease and Large Vessel Occlusion Stroke in Multivariate Regression

After stratification for ethnicity and race in multivariate analysis, the presence of COVID-19 exhibited a significant independent association (p = 0.011) with LVO stroke (odds ratio, 2.4) compared with the absence of COVID-19 (Table 3). No other stroke-related risk factor was associated with LVO in the multivariate analysis.
TABLE 3: Results of Multivariate Logistic Regression Assessing the Association Between Patient Characteristics and Large Vessel Stroke, Controlled for Race and Ethnicity
CharacteristicOdds Ratio for Large Vessel Strokep
COVID-19 present2.4 (2.1–2.7)0.011a
Age (y)0.8 (0.6–1.0)0.622
Male sex0.9 (0.6–1.1)0.744
Diabetes mellitus type 20.9 (0.6–1.2)0.673
Hypertension1.4 (1.0–1.7)0.331
Coronary artery disease0.9 (0.4–1.3)0.962
Congestive heart failure1.1 (0.8–1.4)0.361
Dyslipidemia0.8 (0.5–1.3)0.352
History of smoking1.1 (0.9–1.3)0.421
Atrial fibrillation0.8 (0.5–1.1)0.254
Body mass index1.1 (0.9–1.3)0.722

Note—Values in parentheses are 95% CIs. COVID-19 = coronavirus disease.

a
Statistically significant at p < 0.05.

Discussion

In this study, we observed a significantly greater frequency of LVO strokes in patients with COVID-19 than in patients without COVID-19. After further control for race and ethnicity in multivariate analysis, patients with COVID-19 had an LVO stroke risk 2.4 times that of patients without COVID-19. An association with COVID-19 was not observed for SVO strokes.
To our knowledge, this is the first study to show an association between COVID-19 and large vessel strokes. In our study 62% of the large vessel strokes involved occlusion of the M1-M2 segments of the middle cerebral artery. Results of prior studies suggest that the pathologic mechanism involves direct binding to ACE-2 receptors, which are expressed throughout the endothelial cells of the vasculature, which leads to vascular thrombosis within the vessels through a cytokine storm [68, 27]. This process likely accounts for the increased risk of thrombosis—including deep vein thrombosis [11, 12], pulmonary embolisms [1517], and strokes [18, 28]—in patients with COVID-19. Besides being cryptogenic and in situ occlusion from plaque rupture, LVOs can be cardioembolic and in rare cases can embolize from the venous system by bypassing through a right-to-left shunt, such as a patent foramen ovale. Although cardioembolic causes can be considered, multifocal occlusion was observed in only 9.9% of patients with LVOs in our study.
We conducted this retrospective study because of our anecdotal observation of an increased frequency of acute strokes in patients presenting with acute neurologic symptoms during the COVID-19 pandemic. We included stroke code patients presenting during the COVID-19 pandemic who underwent emergency stroke workups. Race or ethnicity was the only stroke-related risk factor associated with COVID-19 status; specifically, a significantly greater proportion of Hispanic patients had COVID-19. A prior report [29] also showed a disproportionate impact of COVID-19 on the Hispanic community in New York City.
Many of the common vascular comorbidities were not associated with LVOs in our study, likely owing to the small sample size. Erythrocyte sedimentation rate and C-reactive protein level are commonly elevated in a cytokine storm and are associated with severe COVID-19 [30]. These inflammatory markers were elevated in patients with COVID-19 compared with negative control subjects, although the difference was not significantly different. Obesity has also been associated with severe forms of COVID-19, as found in a study showing that higher body mass index was associated with a significant increase in morbidity [31]. However, we did not observe a significant association between body mass index and COVID-19 status.
The association between LVO strokes and COVID-19 has important clinical implications. Although the incidence of SARS-CoV-2 infection in New York City is declining, a large population of patients continue to present with COVID-19. Patients with active SARSCoV-2 infection should be monitored closely, especially if they present with acute neurologic symptoms, with a lower threshold of suspicion of LVOs. Health care providers in the emergency department and inpatient areas should be cognizant of this association and not delay activating a stroke code. This association may aid neurointerventionalists assessing the presence and location of an LVO if they are aware of this elevated risk in the COVID-19 population. Additionally, this association may imply that patients with LVO during the COVID-19 pandemic who have not undergone testing for SARS-CoV-2 infection or are waiting for results warrant higher suspicion and appropriate precautions.
There were several limitations to our study. First, we used the reference standard of RT-PCR from a nasal swab, the sensitivity and specificity of which for diagnosis of COVID-19 have not been definitively established. Although the test is being routinely used to assess for COVI-19 status, it was approved under emergency use authorization and has recently been found to have a sensitivity as low as 70% [2325]. To address this problem, we assessed clinical manifestations and chest CT and CT angiography findings to identify likely false-negative diagnoses based on RT-PCR results, although only six patients with negative RTPCR results were classified as having COVID-19 on this basis. Second, because this was a retrospective study, we could not control for possible unknown confounding variables. We attempted to overcome confounding effects of common stroke-related risk factors by assessing the association between these factors and COVID-19 status and incorporating such risk factors into a multivariate analysis. Finally, we acknowledge that this study may show an association between COVID-19 and LVO strokes, but we did not evaluate causality.
To our knowledge, this is the first study to describe an association between COVID-19 and large vessel strokes. Patients with COVID-19 presenting with acute neurologic symptoms warrant a lower threshold of suspicion of large vessel stroke, and prompt workup for large vessel stroke is recommended. Future investigation may focus on the exact pathophysiologic mechanism of large vessel strokes in patients with COVID-19 and validate contributing risk factors through a larger study.

Acknowledgments

We thank Zahi A. Fayad and Valentin Faveau of the Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, for contributions in revision of this article. We also thank the Mount Sinai COVID Informatics Center.

References

1.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506
2.
World Health Organization website. WHO Director-General's opening remarks at the media briefing on COVID-19: 11 March 2020. www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020. Published March 11, 2020. Accessed March 13, 2020
3.
Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al.; Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19). Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis 2020; 34:101623
4.
Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 1127:2–9
5.
Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020; 382:2268–2270
6.
Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 135:2033–2040
7.
Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 2020 Apr 17 [Epub ahead of print]
8.
Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020; 382:e38
9.
Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme–related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87:E1–E9
10.
Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty 2020; 9:45
11.
Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol 2020; 189:846–847
12.
Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191:145–147
13.
Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med 2020; 38:1504–1507
14.
Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020; 75:2352–2371
15.
Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J 2020; 41:1858
16.
Cellina M, Oliva G. Acute pulmonary embolism in a patient with COVID-19 pneumonia. Diagn Interv Imaging 2020; 101:325–326
17.
Grillet F, Behr J, Calame P, Aubry S, Delabrousse E. Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography. Radiology 2020 Apr 23 [Epub ahead of print]
18.
Oxley TJ, Mocco J, Majidi S, et al. Large-stroke as a presenting feature of COVID-19 in the young. N Engl J Med 2020; 382:e60–e64
19.
Moshayedi P, Ryan TE, Mejia LLP, Nour M, Liebeskind DS. Triage of acute ischemic stroke in confirmed COVID-19: large vessel occlusion associated with coronavirus infection. Front Neurol 2020; 11:353–355
20.
El Husseini N, Goldstein LB. “Code stroke”: hospitalized versus emergency department patients. J Stroke Cerebrovasc Dis 2013; 22:345–348
21.
Gorelick AR, Gorelick PB, Sloan EP. Emergency department evaluation and management of stroke: acute assessment, stroke teams and care pathways. Neurol Clin 2008; 26:923–942
22.
Ekundayo OJ, Saver JL, Fonarow GC, et al. Patterns of emergency medical services use and its association with timely stroke treatment: findings from Get With the Guidelines-Stroke. Circ Cardiovasc Qual Outcomes 2013; 6:262–269
23.
Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. J Med Virol 2020; 92:903–908
24.
Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 2020 Feb 26 [Epub ahead of print]
25.
Winichakoon P, Chaiwarith R, Liwsrisakun C, et al. Negative nasopharyngeal and oropharyngeal swabs do not rule out COVID-19. J Clin Microbiol 2020; 58:1–7
26.
Rennert RC, Wali AR, Steinberg JA, et al. Epidemiology, natural history, and clinical presentation of large vessel ischemic stroke. Neurosurgery 2019; 85(suppl 1):S4–S8
27.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033–1034
28.
Avula A, Nalleballe K, Narula N, et al. COVID-19 presenting as stroke. Brain Behav Immun 2020; 87:115–119
29.
NBC New York website. Hispanic community in NYC “disproportionately” impacted by COVID-19: officials. www.nbcnewyork.com/news/coronavirus/hispanic-community-in-nyc-disproportionately-impacted-by-covid-19-officials/2365896. Published April 8, 2020. Updated May 6, 2020. Accessed May 28, 2020
30.
Liu T, Zhang J, Yang Y, et al. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med 2020 May 19 [Epub ahead of print]
31.
Caussy C, Wallet F, Laville M, Disse E. Obesity is associated with severe forms of COVID-19. Obesity (Silver Spring) 2020; 27:1175

FOR YOUR INFORMATION

This article has been selected for AJR Journal Club activity. The accompanying Journal Club Study Guide can be found on the following page.

Study Guide

Association of Coronavirus Disease (COVID-19) With Large Vessel Occlusion Strokes: A Case-Control Study

Alan Mautz, MD1, Joseph J. Budovec, MD2
1Northern Light AR Gould Hospital, Presque Isle, ME.
2Medical College of Wisconsin, Milwaukee, WI.
*Please note that the authors of the Study Guide are distinct from those of the companion article.

Introduction

1. What neurologic manifestations of coronavirus disease (COVID-19) have been described?
2. What is the proposed mechanism of endothelial injury in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection?
3. What is the stated purpose of this study?

Methods

4. What type of study is used to evaluate the clinical question?
5. Does the study have a stated hypothesis? What is the null hypothesis?
6. How were patients enrolled in this study? What was the final sample size?
7. What risk factors for stroke were considered in this study? What were the means of diagnosing COVID-19?
8. What are the limitations of this study? Are these limitations adequately discussed?

Results

9. How much more likely were patients with COVID-19 to have large vessel occlusion (LVO) infarcts compared with those without?
10. What vessel or vessels were most commonly involved in patients with COVID-19?

Discussion

11. Do the data presented here support the clinical implications suggested in this study, including changes in neurologic monitoring for patients with COVID-19?
12. What changes to imaging orders, if any, would you suggest to clinicians at your institution caring for COVID-19 patients with neurologic symptoms when a code stroke is called?
13. The study admits the limitation of showing an association between LVO strokes and COVID-19 rather than a causal relationship. How does this affect your approach to the data presented and conclusions drawn in this study?

Background Reading

1.
Grillet F, Behr J, Calame P, Aubry S, Delabrousse E. Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography. Radiology 2020; 296:E186–E188
2.
Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med 2020; 38:1504–1507

Information & Authors

Information

Published In

American Journal of Roentgenology
Pages: 150 - 156
PubMed: 32755225

History

Submitted: May 15, 2020
Revision requested: May 26, 2020
Revision received: May 29, 2020
Accepted: June 5, 2020
Version of record online: July 29, 2020

Keywords

  1. coronavirus disease
  2. COVID-19
  3. ischemic strokes
  4. large vessel strokes

Authors

Affiliations

Shingo Kihira, MD
Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, Box 1234, New York, NY 10029
Javin Schefflein, MD
Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, Box 1234, New York, NY 10029
Keon Mahmoudi, BS
Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, Box 1234, New York, NY 10029
Brian Rigney, MD
Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, Box 1234, New York, NY 10029
Bradley N. Delman, MD, MS
Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, Box 1234, New York, NY 10029
J Mocco, MD
Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, Box 1234, New York, NY 10029
Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY
Amish Doshi, MD
Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, Box 1234, New York, NY 10029
Puneet Belani, MD
Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, Box 1234, New York, NY 10029

Notes

Address correspondence to S. Kihira ([email protected]).
The authors declare that they have no disclosures relevant to the subject matter of this article.

Metrics & Citations

Metrics

Citations

Export Citations

To download the citation to this article, select your reference manager software.

Articles citing this article

View Options

View options

PDF

View PDF

PDF Download

Download PDF

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media